We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

24 hedge funds and large institutions have $13.8M invested in Regulus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

14.01% more ownership

Funds ownership: 41.57% → 55.58% (+14%)

10% more capital invested

Capital invested by funds: $12.6M → $13.8M (+$1.24M)

11% less funds holding

Funds holding: 27 → 24 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
24
Holders Change
-3
Holders Change %
-11.11%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
4
Closed
7
Calls
$1.14M
Puts
–
Net Calls
+$1.14M
Net Calls Change
-$144K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.95M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$56.9K
3
BlackRock
BlackRock
New York
+$42.7K
4
HF
HRT Financial
New York
+$40.9K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$20.7K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$217K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$162K
3
Citadel Advisors
Citadel Advisors
Florida
-$42.6K
4
BFM
Boothbay Fund Management
New York
-$24K
5
VF
Virtu Financial
New York
-$21K

RGLS Hedge Fund Activity: Q3 2022 in Review

24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2022, worth a combined $13.8M — up 9.8% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RGLS and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $3.95M. The largest seller was Ikarian Capital, exiting entirely with an estimated $217K sold.

  • 24 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2022, down from 27 in Q2 2022.
  • Funds reported $13.8M of Regulus Therapeutics stock for Q3 2022, up 9.8% quarter-over-quarter.
  • 4 funds opened new Regulus Therapeutics positions in Q3 2022 and 7 closed out, a net change of -3 holders.
  • The largest Regulus Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $3.95M added.
  • The largest Regulus Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $217K sold.

Based on aggregated 13F filings for Q3 2022.